Table 2.

An overview of positive prognostic factors per article category (primary resection, hepatic resection, pulmonary resection, ablation and embolization).

Treatment	Positive Prognostic Factors— Patient Characteristics	Positive Prognostic Factors— Disease Characteristics (Primary Tumor)	Positive Prognostic Factors— Disease Characteristics (Metastases)	Positive Prognostic Factors—Treatment(s)
Primary resection	Younger age [20,21] Caucasian ethnicity [20,21] Married [20,21] Female [20,21] Later era of diagnosis [22]	Tumor in pancreatic head [20] Well/moderate differentiation of tumor (histological grade) [20,22,23]	Longer DFI [23] Single-organ metastatic disease [23]	Chemotherapy (pre- and/or post local treatment) [20,22] Primary tumor resection [20,21,22,23] Local metastatic treatment [21]
Hepatic resection		Lower tumor stage [24,25] Tumor in pancreatic body/tail [26] Smaller primary tumor size [27] Well/moderate differentiation of tumor (histological grade) [25] Lower tumor marker CA19-9 levels pre- or post-treatment(s) [25,28,29]	Fewer and/or smaller liver lesions [28] Metachronous (instead of synchronous) [30] Absence of lymph node status [25,31]	Chemotherapy (pre- and/or post local treatment) [25,28,29] Primary tumor resection [28,29] Better primary resection status [24,31] Better liver resection status [25]
Pulmonary resection		Well/moderate differentiation of tumor (histological grade) [32] Lower tumor marker CA19-9 levels pre- and/or post-treatment(s) [33,34]	Fewer and/or smaller lung lesions [34,35] Longer DFI [32,34,36]
Ablation	Younger age [37] Performance status 0–1 [37]	Lower tumor stage [38] Tumor in pancreatic body/tail [39] Well/moderate differentiation of tumor (histological grade) [37,38,40] Neutrophil-to-lymphocyte ratio (NLR) < 2.5 [38]	Fewer and/or smaller liver/lung lesions [37,38,39,40,41] Longer DFI [38,42] Single-organ metastatic disease [38]
Embolization	Male [43]	Smaller primary tumor size [44] Lower tumor marker CA19-9 levels pre- or post-treatment(s) [45] Absence of ascites [44] Decreased albumin and bilirubin prior to local treatment [46]	Fewer and/or smaller liver/lung lesions [47] Single-organ metastatic disease [48]	Primary tumor resection [46] Local metastatic treatment [44]